Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Myriad Genetics Inc | MYGN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
18.49 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 13.82 - 24.21 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 18.49 | USD |
Myriad Genetics (MYGN) Options Flow Summary
Myriad Genetics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.66B | 89.87M | - | 753.2M | -263.3M | -2.93 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Myriad Genetics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MYGN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 18.66 | 19.31 | 18.21 | 18.60 | 524,357 | -0.17 | -0.91% |
1 Month | 22.12 | 22.2699 | 18.21 | 20.01 | 545,760 | -3.63 | -16.41% |
3 Months | 22.72 | 23.75 | 18.21 | 21.52 | 626,925 | -4.23 | -18.62% |
6 Months | 14.96 | 23.75 | 13.82 | 19.85 | 667,435 | 3.53 | 23.60% |
1 Year | 22.43 | 24.21 | 13.82 | 19.69 | 598,380 | -3.94 | -17.57% |
3 Years | 29.25 | 36.9547 | 13.82 | 22.69 | 577,261 | -10.76 | -36.79% |
5 Years | 32.08 | 48.40 | 9.24 | 22.45 | 730,358 | -13.59 | -42.36% |
Myriad Genetics Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies. |